anticancer

Anticancer agent 3 (Compound 4) is a anti-cancer agent.

Compound 6i, an anticancer agent, exhibits promising activity against breast adenocarcinoma [1].

Compound 166, also referred to as compound 3, exhibits potent anticancer properties, demonstrating significant inhibitory activity against Caco-2 cells with an IC50 value of 9.6 nM [1].

Anticancer agent 112[1], serves as a potent agent for cancer research.

Compound 103 (Compound 2k) serves as a potent anticancer agent [1].

Anticancer agent 160 (Compound 6), a natural product extracted from Parthenium hysterophorus, exhibits cytotoxicity against HCT-116 cells with an IC50 of 5.0 μM [1].

Compound 3a, an anticancer agent and ketone derivative, exhibits potent activity against the A549 cancer cell line, demonstrating an inhibitory concentration (IC50) of 6.62 μM [1].

Anticancer agent 126 (compound 12), a WDR5 inhibitor, exhibits anticancer properties by disrupting the WDR5-MYC interaction in cells, subsequently reducing MYC target gene expression [1].

Anticancer agent 158 (compound 7c) demonstrates potent efficacy against various cancer cell lines, with IC50 values of 7.93 μM for HepG-2, 9.28 μM for MDA-MB-231, and 13.28 μM for HCT-116; however, it exhibits reduced potency with an IC50 of 181.89 μM against an unspecified cell line [1].

Anticancer Agent 149 (compound 3), isolated from the rhizome of Dioscorea dioscorea (DM), demonstrates selective cytotoxicity against MCF-7 cells with an IC50 of 31.41 μM [1].

Compound 107 (Compd 11jc) exhibits potent antitumor activity and serves as an effective anticancer agent in the investigation of pulmonary metastatic melanoma [1].

Anticancer agent 33 (compound 3), derived from Squamocin and Bullatacin, exhibits potent inhibitory activity against the 4T1 breast cancer cell line (A549, HeLa, HepG2, and MCF-7 cells), with IC50 values ranging from 1.9 to 5.4 µM [1].

Anticancer agent 94, a 4-Hydroxycoumarin derivative, inhibits lung cancer cell invasion and migration by modulating the expression of epithelial-mesenchymal transition (EMT) effectors [1].

Anticancer Agent 93, a 4-Hydroxycoumarin derivative, inhibits the invasion and migration of lung cancer cells through modulation of epithelial-mesenchymal transition (EMT) effector expression [1].

Compound 6a (Anticancer Agent 171), an oxime analogue, demonstrates anticancer activity by inhibiting HCT116 cells with an IC50 of 3.43 μM and may be utilized for cancer research [1].

Anticancer agent 162 (compound 1d) serves as a potent theranostic agent, selectively inducing oncosis in Hela cells with pronounced lipophilicity and cytotoxicity [1].

HCT-116-IN-1, a γ-lactam-fused pyridone derivative, exhibits anticancer properties, demonstrating significant cytotoxicity towards HCT116 cells, with an IC50 value of 5.59 μM [1].

Anticancer Agent 96 (Compound 4) exhibits cytotoxic activities against human cancer cells [1].

Anticancer agent 154 (Compound 8h) enhances reactive oxygen species production, causing mitochondrial damage, and promotes cell apoptosis and DNA damage. It triggers ferroptosis by depleting GSH, diminishing GPX4 expression, and escalating lipid peroxidation. Furthermore, it effectively suppresses the proliferation of various cancer cells (HT29, H1975, A549, and MCF-7) with IC50 values ranging from 1.0 to 1.9 μM [1].

Quinazolinone Compound 95, also known as Compound 24, exhibits anticancer properties [1].

Compound D16 (Anticancer agent 168) is an inhibitor of DNA2 that induces apoptosis and cell-cycle arrest predominantly in the S-phase. It demonstrates anticancer efficacy and can counteract chemotherapy resistance in cancers harboring mutant p53 [1].

Anticancer Agent 101, a tetracaine derivative, exhibits anti-cancer activity [1].

Anticancer agent 172 (8d) exhibits potent activity against cancer, achieving an IC50 value of 6.96 μM in HCT116 cells [1].

Compound 3b, known as Anticancer Agent 161, is a bioactive alkynol exhibiting potential anticancer properties. It has the capability to induce autophagy and deplete mitochondrial membrane potential [1].

Anticancer agent 113 possesses anticancer activity [1].

Compound 156, also referred to as compound 11, is a potent miliusanes-based anticancer agent that demonstrates effective inhibition of human cancer cell growth and exhibits substantial cytotoxicity against gastric cancer cells [1].

Anticancer agent 136 (compound 22), a C17-triazole analogue of Geldanamycin (GDM), exhibits an IC50 value of 3.38 μM against human dermal fibroblasts (HDF) and binds to Heat shock protein 90 (Hsp90) with a dissociation constant (Kd) of 3.86 μM, demonstrating its apoptosis-inducing capabilities [1].

Anticancer Agent 108 (Compound 3.10) serves as a potent P-gp inhibitor exhibiting considerable antitumor properties while maintaining reduced toxicity to both normal and pseudonormal cells; it also demonstrated no acute toxic effects on C57BL/6 mice [1].

Anticancer Agent 110 exhibits potent in vitro anti-leukemia activity, demonstrating high cytotoxicity against K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. It induces DNA damage and subsequently triggers apoptosis [1].

Anticancer Agent 146 (Compound 1.19) acts as a necroptosis inducer and demonstrates anti-tumor efficacy in the MDA-MB-231 mouse xenograft model [1].

Anticancer Agent 153 (Compound 3) promotes apoptosis through the generation of Reactive Oxygen Species (ROS) and elevates the loss of Mitochondrial Membrane Potential (MMP), effectively inhibiting cancer cell proliferation [1].

Anticancer agent 32 (compound 2g) is an anticancer agent that exhibits anticancer effects by affecting the cell cycle and inducing apoptosis. anticancer agent 32 can be used in cancer research.

Anticancer agent 74 exhibits moderate anticancer activity with lower selectivity and cytotoxicity compared to doxorubicin towards normal cells [1].

Anticancer agent 49 (compound 69) is a broad-spectrum anticancer agent with anti-proliferative activity. anticancer agent 48 inhibits microtubule protein aggregation and has in vivo antitumour activity. anticancer agent 48 has potential for solid tumour and haematological tumour studies. anticancer agent 49 is a broad-spectrum anticancer agent with anti-proliferative activity.

Anticancer agent 59, an inhibitor active against various cancer cell lines, particularly demonstrates efficacy in A549 cells with an IC 50 value of 0.2 μM. It prompts apoptosis, elevates Ca2+ and ROS levels within cancer cells, and markedly reduces mitochondrial membrane potential. Additionally, it effectively curtails tumor growth in the A549 mouse xenograft model.

Anticancer agent 66, a ciprofloxacin analog, functions as an anti-cancer agent by inducing apoptosis and elevating the sub-G1 cell population in MCF-7 cells.

Anticancer Agent 102, a tetracaine derivative, exhibits anti-cancer activity by inducing apoptosis [1].

Anticancer agent 81 (Compound 37b3) induces tumor cell cycle arrest and apoptosis and serves as a payload for conjugation with Trastuzumab, resulting in the antibody-agent conjugate (ADC) T-PBA. T-PBA retains the targeting and internalization properties of Trastuzumab [1].

Anticancer agent 70 (Compound 21) is a potent anticancer compound that demonstrates remarkable cytotoxicity against multiple human cancer cell lines. It induces G0/G1-cell cycle arrest and concurrently elevates the levels of p53 and p21 proteins. Furthermore, Anticancer agent 70 induces ATP depletion and disruption of the mitochondrial membrane potential [1].

Anticancer agent 29 (Compd E/Z-6f) exhibits potent anticancer activity, as indicated by IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, and 0.396 μM for CDK2, CDK1, CDK4, and CDK6, respectively [1].

Anticancer agent 38 (compound 19) is an aryl-urea compound, and is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC 50 of 5.2 μg/mL [1].

Anticancer agent 54 is an effective anticancer agent whose anticancer activity depends on DNA embedding and ROS generation. Anticancer agent 54 has an anti-proliferative effect by blocking the cell cycle in G0/G1 phase and inducing apoptosis.

Anticancer agent 57 (compound 14) demonstrates potent inhibition of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC 50 values ranging from 6.43 to 8.00 μM. Additionally, this agent induces cell cycle arrest and promotes apoptosis. In vivo studies using nude mice xenografted with MADMB-231 cells have shown that Anticancer agent 57 effectively inhibits tumor growth. Consequently, Anticancer agent 57 can serve as a valuable tool for researching triple negative breast cancer (TNBC) [1].

Anticancer agent 34 (compound 9) is a sulfonylurea derivative and a potent anti-microbial and anti-cancer agent. anticancer agent 34 showed inhibition of microbial growth of Mycobacterium, Escherichia coli and Candida albicans (MIC: 0.039-0.156 mg/ml). Anticancer agent 34 inhibited the growth of A549 cells (IC50: 8.4 μg/ml), PC3 cells (IC50: 7.8 μg/ml).

Anticancer agent 79 (compound 3d) is a anticancer compound with good anti-breast cancer activity. Anticancer agent 79 exhibits good cytotoxic activity in T47-D cells (IC50= 13.64 ± 0.26 μM).

Anticancer agent 40 (compound 3e) is a potent anticancer agent that has anticancer effects on SKBR-3 cells (IC50: 0.94 nM), SKOV-3 cells (IC50: 0.98 nM), PC-3 cells (IC50: 0.96 nM), U-87 cells ), U-87 cells (IC50: 0.95 nM), and HDF cells (IC50: 2.13 nM).

Anticancer agent 30 (compound 6f-Z) is a potent anticancer compound. It belongs to the class of 3-arylidene-2-oxindole derivatives and acts as a selective inhibitor of CDK2. Extensive research has demonstrated its significant anticancer activity, making it a promising candidate for cancer treatment [1].

Anticancer Agent 143 (Compound 369), a potent dual inhibitor targeting PTPN2 and PTP1B, exhibits IC50 values below 2.5 nM. It is employed in cancer research [1].

Anticancer Agent 118, an N‑acylated ciprofloxacin derivative, exhibits antibacterial efficacy against Gram-positive strains and antiproliferative effects on prostate PC3 cells, making it a potential candidate for antitumor research [1].

Anticancer agent 50 (compound 6) is a potent modulator of the ABCB1 efflux pump with cytotoxic and anti-proliferative activity. anticancer agent 50 reduces the expression of cyclin D1 and induces p53 expression. anticancer agent 50 has shown potential for research in T lymphoma.